Targets › PREGN
1 program from 1 company in 1 trial: 1 Phase 2; Psychiatry; next expected readout Jun 2028.
Open in Phaseline: the race on PREGN, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| VA Office of Research and Development | Pregnenolone Neurosteroid; modulates GABAergic and glutamatergic neurotransmission | PREGN | Phase 2 | Anxiety and Depression | Jun 2028 |
Anxiety and Depression (1)
small molecule (1)
VA Office of Research and Development (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.